NCT04373031 2025-12-02
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03267680 2025-04-13
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
University of Southern California
Phase 2 Terminated
NCT03918499 2023-03-23
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 1/2 Completed